Transtumoral targeting enabled by a novel neuropilin-binding peptide

Oncogene

Volumn 31, Issue 33, 2012, Pages 3754-3763

  Roth, L ^a,b   Agemy, L ^a,b   Kotamraju, V R ^a,b   Braun, G ^a   Teesalu, T ^a,b   Sugahara, K N ^b   Hamzah, J ^a,b   Ruoslahti, E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

breast cancer; nanoparticles; tumor homing; tumor penetration

Indexed keywords

CYSTEINYLGLYCYLASPARAGINYLLYSYLARGINYLTHREONYLARGININE; CYSTEINYLGLYCYLASPARAGINYLLYSYLARGINYLTHREONYLARGINYLGLYCYLCYSTEINE; NANOPARTICLE; NEUROPILIN 1; NEUROPILIN 2; NONAPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HOMING; EXTRAVASATION; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEUROPILIN-1; NEUROPILIN-2; NEUROPILINS; PEPTIDES, CYCLIC;

EID: 84865258883     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.537     Document Type: Article

References (39)

1. Acevedo LM, Barillas S, Weis SM, Gothert JR, Cheresh DA. (2008). Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 111: 2674-2680.
2. Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM et al. (2011). Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci USA 108: 17450-17455.
3. Agemy L, Sugahara KN, Kotamraju VR, Gujraty K, Girard OM, Kono Y et al. (2010). Nanoparticle-induced vascular blockade in human prostate cancer. Blood 116: 2847-2856.
4. Bagri A, Tessier-Lavigne M, Watts RJ. (2009). Neuropilins in tumor biology. Clin Cancer Res 15: 1860-1864.
5. Becker PM, Waltenberger J, Yachechko R, Mirzapoiazova T, Sham JS, Lee CG et al. (2005). Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ Res 96: 1257-1265. (Pubitemid 40962103)
6. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK et al. (2008). Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13: 331-342. (Pubitemid 351446192)
7. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M. (1997). Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 19: 547-559. (Pubitemid 27430744)
8. Dallas NA, Gray MJ, Xia L, Fan F, van Buren 2nd G, Gaur P et al. (2008). Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res 14: 8052-8060.
9. Ellis LM. (2006). The role of neuropilins in cancer. Mol Cancer Ther 5: 1099-1107. (Pubitemid 43881301)
10. Fogal V, Zhang L, Krajewski S, Ruoslahti E. (2008). Mitochondrial/ cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68: 7210-7218.
11. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. (2000). Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 275: 18040-18045.
12. Greish K. (2007). Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 15: 457-464. (Pubitemid 47209047)
13. Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G. (2006). The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett 231: 1-11. (Pubitemid 41779447)
14. Hamzah J, Kotamraju VR, Seo JW, Agemy L, Fogal V, Mahakian LM et al. (2011). Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 108: 7154-7159.
15. Haspel N, Zanuy D, Nussinov R, Teesalu T, Ruoslahti E, Aleman C. (2011). Binding of a C-end rule peptide to the neuropilin-1 receptor: a molecular modeling approach. Biochemistry 50: 1755-1762.
16. He Z, Tessier-Lavigne M. (1997). Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 90: 739-751. (Pubitemid 27357965)
17. Heldin CH, Rubin K, Pietras K, Ostman A. (2004). High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813. (Pubitemid 39331152)
18. Hoffman JA, Giraudo E, Singh M, Zhang L, Inoue M, Porkka K et al. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4: 383-391. (Pubitemid 37491099)
19. Hynes RO. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687. (Pubitemid 35283958)
20. Jain RK. (1999). Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1: 241-263. (Pubitemid 129740012)
21. Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, Tirrell M et al. (2009). Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 5: 73-82.
22. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. (1997). Neuropilin is a semaphorin III receptor. Cell 90: 753-762. (Pubitemid 27357966)
23. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T et al. (2004). Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 101: 9381-9386. (Pubitemid 38812883)
24. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. (2002). A tumorhoming peptide with a targeting specificity related to lymphatic vessels. Nat Med 8: 751-755. (Pubitemid 34778730)
25. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y et al. (2007). Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 366: 815-829. (Pubitemid 46175863)
26. Mamluk R, Klagsbrun M, Detmar M, Bielenberg DR. (2005). Soluble neuropilin targeted to the skin inhibits vascular permeability. Angiogenesis 8: 217-227. (Pubitemid 41759146)
27. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N et al. (2007). Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11: 53-67. (Pubitemid 46054517)
28. Park JH, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ et al. (2009). Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5: 694-700.
29. Ruoslahti E. (2002a). Specialization of tumour vasculature. Nat Rev Cancer 2: 83-90. (Pubitemid 37328795)
30. Ruoslahti E. (2002b). Drug targeting to specific vascular sites. Drug Discov Today 7: 1138-1143. (Pubitemid 35346421)
31. Ruoslahti E, Bhatia SN, Sailor MJ. (2010). Targeting of drugs and nanoparticles to tumors. J Cell Biol 188: 759-768.
32. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745. (Pubitemid 28155313)
33. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM et al. (2009). Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520.
34. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR et al. (2010). Coadministration of a tumorpenetrating peptide enhances the efficacy of cancer drugs. Science 328: 1031-1035.
35. Takagi S, Tsuji T, Amagai T, Takamatsu T, Fujisawa H. (1987). Specific cell surface labels in the visual centers of Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol 122: 90-100. (Pubitemid 17113172)
36. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. (2009). C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106: 16157-16162.
37. Thorek DL, Chen AK, Czupryna J, Tsourkas A. (2006). Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 34: 23-38.
38. Uchida M, Kosuge H, Terashima M, Willits DA, Liepold LO, Young MJ et al. (2011). Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano 5: 2493-2502.
39. von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J et al. (2008). In vivo tumor cell targeting with 'click' nanoparticles. Bioconjug Chem 19: 1570-1578.